Myelomas
207495: A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM3)
- Details
ClinicalTrials.gov ID:
NCT04162210
Diagnosis Type:
NA
USOR Number:
- Address
8820 Huron St
Thornton, CO 80260
P: (303) 386-7622